ADMS Adamas Pharmaceuticals Inc.
11.11
+0.12 (+1%)
Previous Close
10.99
Open
11
Price To Book
2.66
Market Cap
303697772
Shares
27,335,533
Volume
189,609
Short Ratio
Av. Daily Volume
547,103
NewsSee all news
- Adamas Pharmaceuticals (ADMS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
- Adamas to Present at Two Upcoming Investor Conferences
- Adamas to Announce Fourth Quarter and Year-End 2018 Financial Results and Host Conference Call on March 4, 2019
- Tenet Healthcare (THC) Q4 Earnings: What's in the Offing?
- Can Segmental Growth Fuel Veeva Systems' (VEEV) Q4 Earnings?
SEC filingsSee all SEC filings
- SC 13G - Statement of acquisition of beneficial ownership by individuals 19606893
- SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19604746
- SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19597645
- SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19589148
- SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19585436
Drug Information
Drug catalyst information is displayed when you hover over the stage bar graph.
Phase 1b top-line data released September 7, 2017. Pivotal Phase 3 trial to be initiated 2019.
ADS-4101
Partial onset seizures in patents with epilepsy
Approved December, 24 2014.
Namzaric
Moderate to severe dementia of the Alzheimer's type.
Approval announced August 24, 2017.
ADS-5102
Levodopa-Induced Dyskinesia
Phase 3 open-label data released April 19, 2018.
GOCOVRI (amantadine)
Dyskinesia patients with Parkinson's disease
Latest News
- Adamas Pharmaceuticals (ADMS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
- Adamas to Present at Two Upcoming Investor Conferences
- Adamas to Announce Fourth Quarter and Year-End 2018 Financial Results and Host Conference Call on March 4, 2019
- Tenet Healthcare (THC) Q4 Earnings: What's in the Offing?
- Can Segmental Growth Fuel Veeva Systems' (VEEV) Q4 Earnings?
- AptarGroup (ATR) to Report Q4 Earnings: What's in Store?
- Should You Be Worried About Insider Transactions At Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS)?
- Adamas Announces New Employment Inducement Grant
- Is a Beat in Store for Molina Healthcare (MOH) Q4 Earnings?
- Report: Exploring Fundamental Drivers Behind Roku, AECOM, 1-800 FLOWERS.COM, Eldorado Resorts, Haverty Furniture Companies, and Adamas Pharmaceuticals — New Horizons, Emerging Trends, and Upcoming Developments
- LD Micro Welcomes Nearly 1,000 Companies to the LD Micro Index
- Here's Why These Small-Cap Pharma Stocks Lost as Much as 45% in December
- Adamas Provides Preliminary Fourth Quarter and Full-Year 2018 GOCOVRI™ Sales Results and Outlines Key Priorities for 2019
- The Daily Biotech Pulse: Pfizer-Glaxo Set Up Consumer Health Care Venture, New Patent For Adamas
- Adamas Announces Issuance of New U.S. Patent Covering GOCOVRI™
- Is Adamas Pharmaceuticals Inc (ADMS) A Good Stock To Buy?
- Why Adamas Pharmaceuticals, Inc. Stock Continued to Slide in November
- Edited Transcript of ADMS earnings conference call or presentation 1-Nov-18 8:30pm GMT
SEC Filings
- SC 13G - Statement of acquisition of beneficial ownership by individuals 19606893
- SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19604746
- SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19597645
- SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19589148
- SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19585436
- SC 13G - Statement of acquisition of beneficial ownership by individuals 19576518
- SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19563318
- SC 13G - Statement of acquisition of beneficial ownership by individuals 19546552
- 8-K - Current report 19512245
- SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19500231